AMYLOIDOGENIC INDUCTION OF CELLULAR SENESCENCE IN ALZHEIMER'S DISEASE

阿尔茨海默病中细胞衰老的淀粉样诱导

• 批准号: 10044065
• 负责人: Morgan Elyse Levine
• 金额: $ 41.2万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10044065
• 关键词: ATAC-seq; Affect; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease brain; Alzheimer' s disease model; Alzheimer' s disease patient; Alzheimer' s disease risk; Amyloid; Animal Model; Astrocytes; Automobile Driving; Autopsy; Behavior; Binding; Biological Assay; Biological Markers; Biology; Biophysics; Brain; Brain region; Cell Aging; Cells; Characteristics; Chemicals; Coupled; DNA Methylation; Data; Development; Disease; Endothelial Cells; Environment; Epigenetic Process; Exhibits; Exposure to; Fatty Acids; Fibroblasts; Genes; Genetic; Genetic Transcription; Genomic Instability; Gold; Grant; Human; Hydrogen Peroxide; In Vitro; Inflammatory; Ionizing radiation; Link; Lipids; Machine Learning; Measurement; Measures; Membrane Proteins; Mesenchymal Stem Cells; Microglia; Modeling; Molecular; Molecular Profiling; Nerve Degeneration; Neuraxis; Neuroglia; Neurologic; Oncogene Activation; Pathogenesis; Pathologic; Pathway Analysis; Patients; Peripheral; Phenotype; Physiological; Play; Radiation; Role; Sampling; Severity of illness; Signal Transduction; Slice; Solubility; Techniques; Testing; Therapeutic; Tissues; Validation; abeta oligomer; age related; base; biological systems; biomarker development; biophysical techniques; brain cell; cell type; disorder control; experimental study; human tissue; in vivo; irradiation; molecular modeling; molecular phenotype; nervous system disorder; neuroinflammation; novel; novel marker; oligodendrocyte progenitor; reconstitution; response; senescence; simulation; single-cell RNA sequencing; stem cells; stressor; structured data; tau Proteins; telomere; therapeutic target

PROJECT SUMMARY Cellular senescence, one of the major hallmarks of aging, describes the sudden inability for cells to divide. Senescent cells often accumulate with age, in response to physical and chemical stressors (genomic instability, telomere attrition, irradiation, etc.), though the overlap between these stressors and neurological diseases such as Alzheimer’s Disease (AD) is currently unknown. In-vitro experiments of senescence often utilize contrived stressors such as hydrogen peroxide or radiation, that may not be physiologically relevant for age-related diseases such as AD. Furthermore, the senescence phenotypes observed in vitro are likely not complete models for what is occurring in dynamic biological systems. Soluble amyloid-beta oligomers (Abo), an important hallmark in AD, have been shown to potently induce senescence in a variety of brain cell types and environments, in contrast to fibrillar Ab. Abo is thought to bind membrane proteins and subsequently signal downstream aggregation of related amyloids such as tau. In fact, the presence of endogenous Abo is one of the strongest indicators of disease severity in AD models and organisms, suggesting a link between AD and cellular senescence that is only beginning to be explored. In order to study this association, we propose to combine gold-standard techniques and single-cell omics data in order to define heterogenous genetic and epigenetic signatures of senescence that are distinctly a function of their induction type. Doing so will also produce robust signatures and biomarkers of senescence in brain cells that can be utilized for the pathological phenotyping of human tissues. These measures will also allow for the comparison of disparate senescent behaviors to help identify lab-derived amyloids that best resemble patient-derived constructs. We will evaluate multiple lab-derived Abo constructs, including those stabilized from lipids located in predominantly diseased regions of the brain. Observations would be synergistically coupled with solution biophysics experiments and molecular modeling, providing analogous structural data for each inducer type. Taken together, these measurements will uniquely profile senescence in brain cells, define the degree of overlap between endogenous senescence inducers and those reconstituted in the lab, and highlighting how AD risk is modulated by cellular senescence.

项目摘要 细胞衰老是衰老的主要标志之一，描述了细胞突然无法分裂。 衰老细胞通常随着年龄的增长而积累，以响应物理和化学应激源（基因组不稳定性， 端粒磨损、照射等），尽管这些压力源和神经系统疾病之间的重叠， 因为阿尔茨海默病（AD）目前尚不清楚。衰老的体外实验通常使用人为的 应激源，如过氧化氢或辐射，可能与年龄相关的生理学无关 疾病如AD。此外，在体外观察到的衰老表型可能不是完整的模型 在动态生物系统中发生的事情。 可溶性β-淀粉样蛋白低聚物（Abo）是AD的重要标志，已显示可有效诱导 衰老在各种脑细胞类型和环境中，相反，纤维状抗体。Abo被认为是结合 膜蛋白，并随后向下游发出相关淀粉样蛋白如tau的聚集的信号。事实上， 内源性Abo的存在是AD模型中疾病严重程度的最强指标之一， 这表明AD和细胞衰老之间的联系才刚刚开始探索。 为了研究这种关联，我们建议将联合收割机金标准技术和单细胞组学结合起来 数据，以确定异源的遗传和表观遗传的签名，衰老是明显的， 其感应类型的功能。这样做也将产生强大的签名和生物标志物的衰老， 可用于人类组织病理表型分析的脑细胞。这些措施还将使 用于比较不同的衰老行为，以帮助识别实验室衍生的淀粉样蛋白， 患者衍生的构建体。我们将评估多种实验室来源的ABO构建体，包括那些从 位于大脑主要病变区域的脂质。观察结果将与 溶液生物物理学实验和分子建模，为每个诱导物提供类似的结构数据 类型.总之，这些测量将独特地描绘脑细胞的衰老，定义衰老的程度。 内源性衰老诱导剂和实验室中重建的衰老诱导剂之间的重叠，并强调AD如何 风险是由细胞衰老调节的。